- Home
- GYRE vs PDM Comparison
GYRE vs PDM Comparison
Compare GYRE & PDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- PDM
- Stock Information
- Founded
- GYRE 2002
- PDM 1997
- Country
- GYRE United States
- PDM United States
- Employees
- GYRE N/A
- PDM N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- PDM Building operators
- Sector
- GYRE Health Care
- PDM Real Estate
- Exchange
- GYRE Nasdaq
- PDM Nasdaq
- Market Cap
- GYRE 897.1M
- PDM 948.7M
- IPO Year
- GYRE N/A
- PDM N/A
- Fundamental
- Price
- GYRE $8.21
- PDM $7.81
- Analyst Decision
- GYRE
- PDM Buy
- Analyst Count
- GYRE 0
- PDM 5
- Target Price
- GYRE N/A
- PDM $9.40
- AVG Volume (30 Days)
- GYRE 80.3K
- PDM 963.5K
- Earning Date
- GYRE 08-11-2025
- PDM 07-28-2025
- Dividend Yield
- GYRE N/A
- PDM 4.82%
- EPS Growth
- GYRE N/A
- PDM N/A
- EPS
- GYRE 0.02
- PDM N/A
- Revenue
- GYRE $102,189,000.00
- PDM $565,502,000.00
- Revenue This Year
- GYRE $21.04
- PDM $0.50
- Revenue Next Year
- GYRE $89.64
- PDM N/A
- P/E Ratio
- GYRE $170.09
- PDM N/A
- Revenue Growth
- GYRE N/A
- PDM N/A
- 52 Week Low
- GYRE $6.11
- PDM $5.46
- 52 Week High
- GYRE $19.00
- PDM $11.12
- Technical
- Relative Strength Index (RSI)
- GYRE 60.94
- PDM 58.34
- Support Level
- GYRE $6.62
- PDM $7.42
- Resistance Level
- GYRE $7.47
- PDM $7.92
- Average True Range (ATR)
- GYRE 0.46
- PDM 0.27
- MACD
- GYRE 0.12
- PDM 0.01
- Stochastic Oscillator
- GYRE 99.09
- PDM 83.82
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About PDM Piedmont Office Realty Trust Inc.
Piedmont Realty Trust Inc is a fully integrated, self-managed real estate investment company focused on delivering an exceptional office environment. As an owner, manager, developer and operator of 16 MM SF of Class A properties across major U.S. Sunbelt markets, Piedmont Realty Trust is known for its hospitality-driven approach and commitment to transforming buildings into Piedmont PLACEs that enhance each client's workplace experience.